Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02740114 · ClinicalTrials.gov registry record · Phase 3
Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 105
- Enrollment target
NCT02740114: Clinical Trial Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT02740114 is a Phase 3 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 105 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02740114, a Phase 3 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 105 participants
- Enrollment target
Study Summary
Bupivacaine is a drug that is traditionally given as an injection to numb surgical sites. Liposomes are molecules that are similar to fats. Sometimes drugs are combined with liposomes to make them able to stay in the body for longer periods of time. This has been done with bupivacaine to create liposomal bupivacaine. The goal of this clinical research study is to compare the effects of bupivacaine to those of liposomal bupivacaine when given to patients who are having gynecologic surgery. Researchers want to compare how long the drugs work to numb the wound and how long patients take to recover from surgery.
Interventions
- DRUG Bupivacaine
- DRUG Liposomal Bupivacaine
- DRUG Oxycodone
- BEHAVIORAL Symptom Questionnaire
- BEHAVIORAL Pill Diary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2016-08-31 |
| Est. Completion | 2020-07-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02740114
The ClinicalTrials.gov registry entry for NCT02740114 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bupivacaine is the first listed.
NCT02740114 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02740114 about?
NCT02740114 is a clinical study titled "Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway". Bupivacaine is a drug that is traditionally given as an injection to numb surgical sites. Liposomes are molecules that are similar to fats. Sometimes drugs are combined with liposomes to make them able to stay in the body for longer periods of time. This has been done with bupivacaine to create lipo...
What is the current status of trial NCT02740114?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 105 participants. The study started on 2016-08-31. Estimated completion is 2020-07-23.
What interventions are being tested in trial NCT02740114?
The interventions under investigation include: Bupivacaine (DRUG), Liposomal Bupivacaine (DRUG), Oxycodone (DRUG), Symptom Questionnaire (BEHAVIORAL), Pill Diary (BEHAVIORAL).
Who is sponsoring clinical trial NCT02740114?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.